| Known as |
Drotaverine |
ClinicalTrials.gov intervention name — accepted as the source's own label NCT01236651 ↗2NCT01639027 ↗ NCT00292747 ↗
|
| Known as |
Do-Spa |
“to make the yellowish colored Drotaverine Hydrochloride (Do-Spa®) in-differentiable from the translucent saline solution.” NCT01639027 ↗
|
| Known as |
Drotaverin |
ChEMBL registry synonym — accepted as the source's own label CHEMBL551978 ↗
|
| Known as |
Drotaverina |
ChEMBL registry synonym — accepted as the source's own label CHEMBL551978 ↗
|
| Known as |
Drotaverine Hydrochloride |
“Each participant will randomly take a prefilled syringe with two milliliters of the study medication solution (either Drotaverine Hydrochloride or saline).” NCT01639027 ↗1NCT00731198 ↗
|
| Known as |
Drotin |
ChEMBL registry synonym — accepted as the source's own label CHEMBL551978 ↗
|
| Action |
Inhibit |
“selectively inhibits phosphodiesterase IV” NCT00731198 ↗
|
| Modality |
Small molecule |
“Drotaverine, an isoquinolone derivative” NCT01639027 ↗
|
| Route |
Oral |
“Drotaverine 80 mg plus ibuprofen placebo orally” NCT00292747 ↗
|